Cambridge Financial Group’s Biogen BIIB Stock Holding History

Cambridge Financial Group’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-16,391	Closed	-$6.62M	–	31
2015 Q2	$6.62M	Sell	16,391 -3,774	-19%	-$1.51M	3.53%	9
2015 Q1	$8.51M	Buy	20,165 +18,090	+872%	+$7.13M	4.22%	2
2014 Q4	$704K	Sell	2,075 -20,108	-91%	-$6.51M	3.42%	15
2014 Q3	$7.34M	Sell	22,183 -766	-3%	-$253K	3.67%	6
2014 Q2	$7.24M	Sell	22,949 -1,055	-4%	-$318K	3.6%	7
2014 Q1	$7.34M	Sell	24,004 -1,201	-5%	-$381K	3.73%	3
2013 Q4	$7.05M	Sell	25,205 -3,544	-12%	-$917K	3.59%	7
2013 Q3	$6.92M	Sell	28,749 -5,248	-15%	-$1.17M	3.82%	3
2013 Q2	$7.42M	Buy	+33,997	New	+$7.26M	3.74%	2

Other funds holding BIIB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Cambridge Financial Group's BIIB Position: Q3 2015 in Review

Cambridge Financial Group sold out of Biogen (BIIB) in Q3 2015, closing a stake of 16,391 shares — an estimated $6.62M sold.

Cambridge Financial Group first reported a position in BIIB in Q2 2013 and held it in 9 quarters. The position peaked at $8.51M in Q1 2015. 924 funds tracked by Wall St. Rank hold BIIB as of Q3 2015.

Cambridge Financial Group reported no remaining Biogen position as of Q3 2015 after selling out during the quarter.
Cambridge Financial Group sold 16,391 Biogen shares in Q3 2015, an estimated $6.62M.
Cambridge Financial Group first reported a position in Biogen in Q2 2013 and held it in 9 quarters.
Cambridge Financial Group's Biogen position peaked at $8.51M in Q1 2015.
924 funds tracked by Wall St. Rank held Biogen as of Q3 2015.

Based on Cambridge Financial Group's 13F filing for Q3 2015, filed 12 Nov 2015.